Syngene is excited to be participating in CPHI Barcelona by far the largest and most popular pharma event of the year. We are among the few contract research development and manufacturing organizations (CRDMOs) offering integrated and end-to-end drug development, and manufacturing services across small molecules and biologics.
In a time of high geo-political uncertainty, having a single partner with a broad suite of capabilities as opposed to multiple specialty partners, means being able to manage projects centrally, unhindered by logistical/shipping delays or dependencies on third-party deliverables. This enables timely completion of projects, efficiency, and cost savings.
Throughout our 30 years of history, we have worked with well over 1000 companies and are currently the preferred partner to 400+ global organizations. We are also co-authors of 400+ customer patents. Given our history and experience, we have the capability and experience to design a customized journey to take your molecule from early discovery to commercial manufacturing in the shortest possible time.
The Syngene advantage
Experience in integrated projects
We have 30+ years of experience working with biotechs on integrated Drug Discovery and Development projects.
Extensive study expertise
We have supported 100+ patient-based studies, 60+ clinical trial projects and conducted 800+ BA/BE studies.
Capacity – We invest ahead of need:
New large-scale API facility with quality capacity
Capability to optimize DMTA cycle times
Our development model is designed to optimize Design, Make, Test, Analyze (DMTA) cycle times, enabling scientific decision-making.
Strong project management skills
We have strong project management experience for risk-assessed development and manufacturing
Accredited facilities
Our facilities are US FDA, EMA, ANVISA and PMDA approved; GLP, GMP, ISO certified; AAALAC and CAP accredited; 15+ regulatory and ~250 client audits in the last three years.
Meet our experts
Mahesh Bhalgat
Chief Operating Officer
Ashu Tandon
Chief Commercial Officer
Arul Ramakrishnan
Vice President, Chemical Development
Chetan Tamhankar
Vice President, Clinical Development
Jonathan Hunt
Managing Director and Chief Executive Officer
Mahesh Bhalgat
Chief Operating Officer
Alex Del Priore
Senior Vice President – Manufacturing Services
Ian Grundy
VP Sales Europe/ROW, Development & Manufacturing
Pravinkumar Prajapati
AGM, Business Development, Biologics
Philippe Martel
Executive Director Sales, EU, Development & Manufacturing
Yogesh Shinde
Executive Director Sales, Small molecules manufacturing
Philippe Martel
Executive Director Sales, EU, Development & Manufacturing
Yogesh Shinde
Executive Director Sales, Small molecules manufacturing
Rahul Dwivedi
Global Business Development, Clinical Development
Our services
Small Molecule Development and Manufacturing
Syngene offers chemical development, formulation, analytical, clinical development, and manufacturing services across small molecules, oligonucleotides, HPAPIs, and performance and specialty materials.
Biologics Development and Manufacturing
Syngene offers biologics development and manufacturing solutions for both mammalian and microbial systems. We also offer services from our sterile Fill-Finish facility and Viral Testing facility.
Clinical Development
Syngene offers BA/BE studies for generic drugs, clinical trial management (Phase1-3), central laboratory services, regulated bioanalytical lab services, clinical data management, and biometric services.
Animal Health
Syngene offers comprehensive Animal Healthcare services across the drug discovery, development, and manufacturing continuum for small molecules and biologics.
Syngene International Limited. All rights reserved © 2023